间充质干细胞治疗强直性脊柱炎的临床疗效

doi:10.3969/j.issn.1006-6233.2017.11.030

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (1353 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the clinical efficacy of mesenchymal stem cells in patients with ankylosing spondylitis (AS). Methods: A retrospective study was conducted on 82 patients with AS from May 20 to May 2017. Among them, 42 patients were treated with mesenchymal stem cells as observation group and 40 patients treated with anti-rheumatic drugs as control group (BASF) score and the brachial ankylosis disease activity index (BASDAI) score were measured before and after treatment, and the changes of liver function, blood pressure index, nighttime pain VAS score, Bath ankylosing spondylitis function index (BASFI) score and Bath ankylosing spondylitis disease activity index Variety. Results: After treatment, the blood transfusion count (RBC), white blood cell count (WBC), platelet count (PLT) and hemoglobin (HB) were observed in [(3.20 ± 0.24) × 10¹²/L], [(893.65 ± 121.85 (106.84±7.68)×10⁹ / L],[(106.84 ± 12.35) g / L], which was significantly different from that before treatment (t = 9.40,30.14,7.08,5.34; P < (AST) and total bilirubin (TBIL) were significantly higher than those in the control group (P <0.05) (T = 3.44, 3.44, 3.02; P <0.05). The patients in the observation group were significantly higher than those in the control group (P <0.05) After treatment, VAS score, BASFI score and BASDAI score were significantly better than before treatment (P <0.05), compared with the control group was also statistically significant (P <0.05). Conclusion: AS patients with mesenchymal stem cell therapy can effectively improve the patient's blood and liver function levels, and can effectively alleviate the clinical symptoms of patients, improve spinal function, the effect is remarkable, worthy of clinical promotion.

Key words： Mesenchymal stem cells Ankylosing spondylitis Liver function Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.11.030 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I11/1864

[1] 汪军,陈路.脐带间充质干细胞移植对强直性脊柱炎患者免疫调节及组织损伤的影响[J].中国组织工程研究,2016,20(1):60~64.
[2] 林滇恬,李晓琳,齐晨越,等.强直性脊柱炎患者血清IL-27水平的测定及临床意义[J].中国医科大学学报,2014,43(1):19~21.
[3] 季明亮,钱邦平,邱勇,等.男女性强直性脊柱炎胸腰椎后凸畸形患者临床特征及生活质量的比较[J].中国脊柱脊髓杂志,2014,21(4):337~343.
[4] Chen L, Shi H, Yuan J, et al. Position 97 of HLA-B, a residue implicated in pathogenesis of ankylosing spondylitis, plays a key role in cell surface free heavy chain expression[J].Ann Rheum Dis,2017, 76(3): 593~601.
[5] 刘婧,贾园,李茹,等.类风湿关节炎合并强直性脊柱炎3例[J].北京大学学报(医学版),2014,46(1):149~154.
[6] 夏青,李晓娜,杨晓,等.强直性脊柱炎患者疾病活动度影响因素的有序多分类Logistic回归分析[J].安徽医科大学学报,2016,51(12):1808~1812.
[7] Bozan N, Alpayci M, Aslan M, et al. Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds[J].Eur Arch Otorhinolaryngol,2016, 273(11): 3663~3672.
[8] Faham M, Carlton V, Moorhead M, et al. Discovery of T cell receptor beta motifs specific to HLA-B27-positive ankylosing spondylitis by deep repertoire sequence analysis[J].Arthritis Rheumatol,2017, 69(4): 774~784.
[9] 孙灵迪,梅传忠,王平均,等.PCR-SBT与IMS-ELISA法在强直性脊柱炎患者HLA-B27检测中的比较[J].现代检验医学杂志,2015(2):16~18.
[10] Wang P, Li Y, Huang L, et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial[J].Cell Transplant,2014, 23(10): 1293~1303.
[11] 孙素和,王鹏,苏春燕,等.强直性脊柱炎患者骨髓间充质干细胞调控巨噬细胞的功能异常[J].中国组织工程研究,2016,20(1):13~19.